louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01111578: Evaluation of a New Enteral Feeding Tube for the Measurement of Esophageal and Gastric Pressure
Official title: Evaluation of a New Enteral Feeding Tube for the Measurement of Esophageal and Gastric Pressure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Respiratory Failure
Lead sponsor: Policlinico Hospital
Sponsor class: OTHER
First posted: 2010-04-27
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients admitted to a general and post-operative intensive care unit and who, for clinical reasons, need the placement of an enteral feeding tube

Brief summary: Investigators aim to evaluate the accuracy in the measurement of the esophageal and gastric pressure of a new enteral feeding tube


Eligibility criteria: Inclusion Criteria:

* Requiring the placement of an enteral feeding tube

Exclusion Criteria:

* esophageal ulcers
* severe coagulophaty
* thrombocytopenia

Primary outcomes:
measure: Accuracy of the measurement of the esophageal and gastric pressure
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
state: MI
Study officials:
affiliation: Fondazione IRRCS Ca' Granda Ospedale Maggiore Policlinico
name: Davide Chiumello, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03218878: Pregnancy Outcomes After Uterine Cavity Expansion
Official title: Pregnancy Outcomes Following Hysteroscopic Expansion of the Uterine Cavity for Patients With Small Cavities and Poor Reproductive Outcomes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Miscarriage
Uterus Abnormal
Infertility
Lead sponsor: Reproductive Medicine Associates of New Jersey
Sponsor class: OTHER
First posted: 2017-07-17
Enrollment: 9
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients at an infertility clinic who are scheduled to undergo hysteroscopic expansion of the uterine cavity

Brief summary: This study seeks to evaluate pregnancy outcomes following hysteroscopic uterine cavity expansion surgery for patients with dysmorphic uterine cavities and poor reproductive histories. Patients already planning to undergo surgery at the recommendation of their physicians will be recruited for participation.

Detailed description: Any patient scheduled to undergo hysteroscopic expansion of the uterine cavity at RMANJ is eligible to participate in the study. Patients will be approached for consent to participate in the study prior to undergoing surgery. If enrolled, outcomes following surgery will be followed and recorded.

Eligibility criteria: Inclusion Criteria:

* Any patient scheduled to undergo hysteroscopic expansion of the uterine cavity

Exclusion Criteria:

* None

Primary outcomes:
measure: Ongoing pregnancy
timeFrame: 2 years
Secondary outcomes:
measure: Change in endometrial volume
timeFrame: 1 month
measure: Time to conceive
timeFrame: 2 years
measure: Chemical pregnancy
timeFrame: 2 years
measure: Clinical pregnancy
timeFrame: 2 years
measure: Pregnancy loss
timeFrame: 2 years
measure: Ectopic pregnancy
timeFrame: 2 years
measure: Live birth
timeFrame: 2 years
measure: Obstetrical complications
timeFrame: 2 years
measure: Gestational age at delivery
timeFrame: 2 years
measure: Birthweight
timeFrame: 2 years
Other outcomes:
Locations:
city: Basking Ridge
country: United States
facility: Reproductive Medicine Associates of New Jersey
state: New Jersey
Study officials:
affiliation: Reproductive Medicine Associates of New Jersey
name: Linnea Goodman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05320978: Association of Preoperative Sarcopenia and Intraoperative Hypotension in Patients Undergoing Minimally Invasive Pylorus Preserving Pancreaticoduodenectomy : Prospective Observational Study
Official title: Association of Preoperative Sarcopenia and Intraoperative Hypotension in Patients Undergoing Minimally Invasive Pylorus Preserving Pancreaticoduodenectomy : Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Patients Undergoing Minimally Invasive Pylorus Preserving Pancreaticoduodenectomy
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2022-04-11
Enrollment: 192
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing minimally invasive pylorus preserving pancreaticoduodenectomy

Brief summary: The aim of this study is to determine whether preoperative sarcopenia (low muscle strength/muscle mass) is correlated with time weighted average intraoperative hypotension in patients undergoing minimally invasive pylorus preserving pancreaticoduodenectomy.


Eligibility criteria: Inclusion Criteria:

1. patients 20 years or older who undergo minimally invasive pylorus preserving pancreaticoduodenectomy

Exclusion Criteria:

1. emergency surgery
2. patients who cannot read consent forms(e.g., illiterate, foreigner, etc.)
3. patients with cognitive dysfunction
4. pregnant, lactating women
5. When hand grip test cannot be performed
6. patients with atrial fibrillation, moderate or severe valvular heart disease, left ventricular ejection fraction less than 35%

Primary outcomes:
measure: time weighted average intraoperative hypotension
timeFrame: Procedure (From the induction of anesthesia to the end of anesthesia)
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei University Health System, Severance Hospital
Study officials:
affiliation: Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea.
name: So Yeon Kim, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03672578: Reducing Sugar-sweetened Beverage Consumption Among Young Adults
Official title: Reducing Sugar-sweetened Beverage Consumption Among Young Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intention
Health Knowledge, Attitudes, Practice
Keywords: Diet
Young Adults
Health messaging
Lead sponsor: University of California, Davis
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2018-09-14
Enrollment: 2971
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: This study aims to test sugar-sweetened beverage (SSB) health labeling elements in an online experiment to determine which elements are the most salient among young adults.


Eligibility criteria: Inclusion criteria:

* ≥18 years of age
* current/recent (\<1 year of graduation) undergraduate student at 3 specific universities
* English-speaking
* consumes at least 2 SSBs per week

Primary outcomes:
measure: SSB Intention
timeFrame: Up to 20 minutes
Secondary outcomes:
measure: SSB Intention (2)
timeFrame: Up to 20 minutes
measure: SSB attitudes
timeFrame: Up to 20 minutes
measure: SSB knowledge
timeFrame: Up to 20 minutes
measure: SSB norms
timeFrame: Up to 20 minutes
Other outcomes:
measure: SSB self-efficacy
timeFrame: Up to 20 minutes
measure: Social interaction
timeFrame: Up to 20 minutes
Locations:
city: Davis
country: United States
facility: University of California, Davis
state: California
Study officials:
affiliation: University of California, Davis
name: Jennifer Falbe, ScD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00566878: Pompe Lactation Sub-Registry
Official title: A Sub-Registry to Determine the Presence of Alglucosidase Alfa in Breast Milk From Women With Pompe Disease Treated With Alglucosidase Alfa.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glycogen Storage Disease
Pompe Disease
Keywords: Glycogen Storage Disease
GSD-II
Pompe Disease
Pompe Disease (Late-Onset)
Acid Maltase Deficiency Disease
Glycogenosis II
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2007-12-04
Enrollment: 2
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Females diagnosed with Pompe Disease and Lactating

Brief summary: The objective is to determine if alglucosidase alfa is present in breast milk from mothers with Pompe Disease being treated with alglucosidase alfa and to measure breast milk production and composition in women with Pompe Disease who receive alglucosidase alfa.


Eligibility criteria: Inclusion Criteria:

* Must be enrolled in Pompe Registry (NCT00231400)
* Must be pregnant and intend to breast-feed or be currently lactating and receive at least one infusion of alglucosidase alfa while lactating
* Provide a signed Patient Information and Authorization form to participate in the sub-registry prior to any sub-registry-related assessments are performed
* Agree to adhere to the sub-registry guidelines for antibody testing and recommended schedule of assessments.

Exclusion Criteria:

* Patients will be excluded from this sub-registry if they have received an investigational drug (excluding alglucosidase alfa in regions where alglucosidase alfa is not commercially available) within 30 days prior to Visit 1 breast milk collection

Primary outcomes:
measure: alglucosidase alfa accumulation in immature (1-3 months post partum) or mature (4-6 months post partum) breast milk sample from mothers with Pompe disease who are being treated with alglucosidase alfa.
timeFrame: 6 Months
measure: breast milk production and composition in women with Pompe disease who receive alglucosidase alfa
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Cambridge
country: United States
facility: Registry participation is worldwide. Facilities not yet active may enroll upon identification of a patient
state: Massachusetts
city: Grand Rapids
country: United States
state: Michigan
Study officials:
affiliation: Genzyme, a Sanofi Company
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT06149078: The Relationship of Serum Uric Acid With Severity of Knee Osteoarthritis
Official title: The Relationship of Serum Uric Acid With Severity of Knee Osteoarthritis
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Knee Osteoarthritis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-11-28
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: - Adult patient (Age\>18 years) with a complaint of knee pain.

Brief summary: Osteoarthritis (OA) is the most prevalent form of arthritis. Its pathogenesis remains poorly understood. Though historically regarded as a disease of mechanical degeneration, it is now appreciated that inflammation plays an important role in OA pathogenesis (Krasnokutsky et al., 2017). The hallmark of OA is the degradation and loss of articular cartilage, although most tissues of the joint become affected, such as bone, synovium, ligaments, menisci (knee), labrum (hip), periarticular fat, and muscle (Englund, 2023).It is believed that there is a pathological link between hyperuricemia and OA Therefore, we conducted a cross-sectional study to evaluate an association between elevated SUA and radiographic OA of the knee) Bipan Shrestha, 2019 (.


Eligibility criteria: Inclusion Criteria:

* Adult patient (Age\>18 years) with a complaint of knee pain.

Exclusion Criteria:

* 1.Any patient with a history of trauma to the knee. 2 Any patient with knee complaints as a part of autoimmune connective tissue disease.

Primary outcomes:
measure: percentage of serum uric acid
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag university Hospital
Study officials:
References:
citation: Englund M. Osteoarthritis, part of life or a curable disease? A bird's-eye view. J Intern Med. 2023 Jun;293(6):681-693. doi: 10.1111/joim.13634. Epub 2023 Apr 2.
citation: Krasnokutsky S, Oshinsky C, Attur M, Ma S, Zhou H, Zheng F, Chen M, Patel J, Samuels J, Pike VC, Regatte R, Bencardino J, Rybak L, Abramson S, Pillinger MH. Serum Urate Levels Predict Joint Space Narrowing in Non-Gout Patients With Medial Knee Osteoarthritis. Arthritis Rheumatol. 2017 Jun;69(6):1213-1220. doi: 10.1002/art.40069. Epub 2017 Apr 28.
citation: Park D, Park YM, Ko SH, Hyun KS, Choi YH, Min DU, Han K, Koh HS. Association of general and central obesity, and their changes with risk of knee osteoarthritis: a nationwide population-based cohort study. Sci Rep. 2023 Mar 7;13(1):3796. doi: 10.1038/s41598-023-30727-4.
Clinical trial NCT02321878: Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)
Official title: Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Diabetes Mellitus, Type 2
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2014-12-22
Enrollment: 1092
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male or female patients with T2DM who the physician has decided to start on treatment with Victoza® in combination with insulin or oral anti-diabetes drug (OAD) other than SU (Sulfonylurea) will be eligible for this study.

Brief summary: This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.


Eligibility criteria: Inclusion Criteria:

* Informed consent obtained before any study-related activities (Study-related activities are any procedure related to recording of data according to the protocol)
* Patients with T2DM (type 2 diabetes mellitus) who the physician has decided to start treatment with Victoza® in combination with insulin or OAD (oral anti-diabetes drug) other than SU (sulfonylurea)
* Male or female, no age limitation

Exclusion Criteria:

* Previous participation in this study or NN2211-3772 Participation is defined as informed consent obtained for this study or enrolment for NN2211-3772
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
* Patients who are on Victoza® or have previously been on Victoza® within 3 month before the enrolment

Primary outcomes:
measure: Number of AEs (adverse events)
timeFrame: Week 0-52
Secondary outcomes:
measure: Number of adverse reactions (ARs)
timeFrame: Week 0-52
measure: Change in HbA1c (glycosylated haemoglobin)
timeFrame: Week 0, week 52
Other outcomes:
Locations:
city: Chichibu-city
country: Japan
facility: Novo Nordisk Investigational Site
city: Koriyama-shi, Fukushima
country: Japan
facility: Novo Nordisk Investigational Site
city: Oyama-shi, Tochigi
country: Japan
facility: Novo Nordisk Investigational Site
city: Tagajo-shi
country: Japan
facility: Novo Nordisk Investigational Site
city: Tokyo
country: Japan
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
Clinical trial NCT00419978: The Significance of Sentinel Node Analysis in Colon Cancer
Official title: The Significance of Sentinel Node Analysis in Colon Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Colon Cancer
Lead sponsor: Legacy Health System
Sponsor class: OTHER
First posted: 2007-01-09
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is for the patient with colon cancer, who is going to have colon cancer surgery. The purpose of this research study is to examine a specific lymph node, called the sentinel node. Lymph nodes are located throughout your body and cancer may spread by means of those lymph nodes. The sentinel node is the one located closest to your tumor. This study will find out if examining the sentinel node can help to predict disease progression. Since the value of this exam is unknown, taking part in this study will not change your clinical care.


Eligibility criteria: Inclusion Criteria:

* All patients must consent to participate in study
* Patients will be tracked for five years
* A blood test (CEA) will be collected every six months
* A CT scan will be performed annually
* A colonoscopy will be performed at 1 and 5 years post-surgery

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Legacy Good Samaritan Hospital and Medical Center
state: Oregon
Study officials:
affiliation: Legayc Health System
name: Mark Whiteford, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02958878: Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair
Official title: Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Postoperative Urinary Retention
Lead sponsor: Ascension Health
Sponsor class: INDUSTRY
First posted: 2016-11-08
Enrollment: 210
Sex: MALE
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Double blinded, randomized controlled prospective study looking at 2 preoperative doses of Tamsulosin an alpha-adrenergic blocker in preventing post-operative urinary retention. A previous study was conducted called "Effectiveness of tamsulosin inprevention of postoperative urinary retention: a randomized double-blind-placebo controlled study" This study involved a tertiary care center involving mostly urological surgical procedures. We look to specifically look at inguinal hernia surgeries in males. The aim of this study is to compare the prophylactic effect of tamsulosin with placebo on postoperative urinary retention. The drug is FDA approved for benign prostatic hypertrophy and urinary retention. It is on formulary at Genesys. Currently there is no standard procedure of prophylactic tamsulosin for urinary retention. Most often post operative patients are given tamsulosin to augment smooth muscle relaxation and spontaneous voiding if the patient is having urinary retention post operatively. We often straight catheterize patients once and start tamsulosin with the goal of avoiding urinary retention and future straight catheterizations or placement of foley catheters


Eligibility criteria: Inclusion Criteria:

* healthy males, who are not taking Tamsulosin regularly who are undergoing elective inguinal hernia repair (laparoscopic, open, and robotic assisted)

Exclusion Criteria:

* Patients who are already taking tamsulosin, terazosin (alpha blocker treatement for BPH) , finasteride, dutasteride ( both 5 alpha reductase inhibitors), sulfa allergy, and lactose allergy

Primary outcomes:
measure: number of Urinary Retention
timeFrame: within 72 hours of surgery
Secondary outcomes:
measure: placebo vs tamsulosin
timeFrame: within 72 hours of surgery
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03833778: Kids + Adolescents Research Learning On Tablet Teaching Aachen
Official title: Kids + Adolescents Research Learning On Tablet Teaching Aachen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Inflammatory Intestinal Diseases (CED)
Lead sponsor: RWTH Aachen University
Sponsor class: OTHER
First posted: 2019-02-07
Enrollment: 30
Sex: ALL
Minimum age (years): 8
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of this study plan is to implement a tablet quiz in the German-speaking area, in order to test the specific knowledge about chronic inflammatory intestinal diseases (CED) concerning pediatric patients in the context of an age-appropriated and interesting digital playing environment, and to process knowledge gaps at the subsequent doctor's contact. The quiz should be combined with a game and can be performed by the patients, while they wait in the ambulance for their doctor's appointment. The investigator's goals are to grasp playfully gaps in the CED knowledge regarding the patients and to use these in the following consulting hour for clarification and advice in line with a better understanding of the disease. With this, the specific knowledge, the understanding of the disease, the therapeutic adherence, and the self-efficacy should improve the self-responsible handling of the disease. In particular, the willingness of the group of older teenagers to transit into the adult medicine can be collected and processed. The investigators want to check the efficacy in a randomized, controlled study with two groups of 15 pediatric CED patients. The hypothesis is that the additional play of the tablet-CED-quiz and the individualized advice have a positive impact on the CED knowledge, the disease activity, the CED-related life quality and the willingness of teenagers for transition.


Eligibility criteria: Inclusion Criteria:

* Female and male children and young adults between 8-21 years
* Diagnosis Morbus Crohn, Colitis ulcerosa or Colitis indeterminate
* Clarification and signed Informed Consent Form
* Patients must know how to write and read in German
* Patients must be able to play independently on the tablet

Exclusion Criteria:

* Age \< 8 years or \> 21 years
* Illiteracy
* Mental or psychomotor disability

Primary outcomes:
measure: knowledge test
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Aachen
country: Germany
facility: Clinic for Pediatrics and Youth Medicine, University Hospital of RWTH Aachen University
state: NRW
Study officials:
affiliation: Clinic for Pediatrics and Youth Medicine, University Hospital of RWTH Aachen University
name: Angeliki Pappa, Dr. med.
role: PRINCIPAL_INVESTIGATOR
References: